-
2022-500699-76-00
5
2023-05-18
Active Systemic Lupus Erythematosus (SLE)
-
2022-502051-56-00
5
2023-04-28
H3 K27M-mutant diffuse glioma
-
2024-516505-23-00
5
2023-03-22
Friedreich ataxia
-
2023-505634-94-00
10
2023-02-02
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythe
-
2022-501090-39-00
5
2022-12-14
Biliary Atresia
-
2022-500783-35-00
5
2022-12-06
Acute Myeloid Leukemia
-
2024-514328-18-00
7
2022-12-06
Spinocerebellar ataxia types 1, 3 and Huntington's disease
-
2024-514139-50-00
5
2022-11-14
Multiple myeloma
-
2024-511430-12-00
1
2022-11-11
Prostate cancer recurrent
-
2023-508389-13-00
5
2022-11-08
Combined endpoint of all-cause mortality, kidney failure, and hospital
-
2023-503442-30-00
5
2022-10-14
Multiple Myeloma
-
2022-500764-35-00
6
2022-10-13
Patients with advanced HER2-negative, hormone receptor positive (HER2n
-
2022-500107-50-00
6
2022-10-12
hilar cholangiocarcinoma
-
2023-510384-36-00
5
2022-09-13
Newly Diagnosed Multiple Myeloma
-
2024-512219-37-00
4
2022-09-06
melanoma
-
2023-504660-41-00
4
2022-07-11
Cholestatic Pruritus in Patients with Primary Biliary Cholangitis (PBC
-
2023-509278-41-00
5
2022-07-04
Early Stage Follicular LymphOma
-
2022-501180-40-00
5
2022-06-17
Ewing Sarcoma
-
2023-503267-42-00
5
2022-06-10
Patients with a histological diagnosis of mismatch- repair deficient h
-
2023-507119-36-00
5
2022-05-09
Malignant melanoma of the skin in patients with locally advanced and f
-
2023-506891-28-00
5
2022-05-02
The target population of interest in this study is participants with l
-
2024-515160-32-00
4
2022-02-02
Short Bowel Syndrome-associated Intestinal Failure (SBS-IF)
-
2023-505438-85-00
5
2022-01-12
Acute myocardial infarction (AMI)
-
2024-510578-25-00
5
2021-11-05
Histologically proven high-risk medulloblastoma, with any of the curre